Granite Point Capital Management, L.P. Dia Medica Therapeutics Inc. Transaction History

Granite Point Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.45 - $9.91 $820,491 - $1.83 Million	-184,380 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$7.76 - $10.43 $2.81 Million - $3.78 Million	-362,475 Reduced 66.28%	184,380 $1.69 Million
Q4 2020 Feb 05, 2021	SELL	$4.13 - $10.14 $413,000 - $1.01 Million	-100,000 Reduced 15.46%	546,855 $5.55 Million
Q3 2020 Nov 06, 2020	BUY	$3.91 - $7.15 $663,233 - $1.21 Million	169,625 Added 35.54%	646,855 $2.74 Million
Q1 2020 May 12, 2020	BUY	$2.25 - $5.64 $562,500 - $1.41 Million	250,000 Added 110.02%	477,230 $1.34 Million
Q3 2019 Oct 30, 2019	SELL	$2.07 - $4.88 $5,671 - $13,371	-2,740 Reduced 1.19%	227,230 $470,000
Q2 2019 Jul 29, 2019	BUY	$2.7 - $4.96 $620,919 - $1.14 Million	229,970 New	229,970 $1.14 Million

3.87M

1.3K

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $116M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.